Novartis Accelerates IND Timelines by Digitalizing CMC Processes

Ensuring the quality, safety, and efficacy of therapeutic products through Chemistry, Manufacturing, and Controls (CMC) generates vast, complex datasets from a wide range of analytical technologies. These datasets are produced by cross-functional teams working across multiple modalities, often without harmonization — making it challenging to extract meaningful insights that support timely, informed decision-making.

Learn how Novartis, a leading global biopharmaceutical company, accelerates time-to-IND by transforming how it manages, integrates, and analyzes CMC data. By implementing Genedata Profiler, Novartis harmonizes multi-source data and converts it into governed, analysis-ready data products. This enables seamless integration across experiments and technologies, supports downstream analytics including AI/ML, and helps teams act faster and with clarity across the CMC lifecycle.